DexCom, Inc.
DXCMDexCom, Inc. is a medical device company specializing in continuous glucose monitoring (CGM) systems for people with diabetes. Founded in 1999, the company develops innovative technologies that provide real-time glucose readings to help manage blood sugar levels more effectively. DexCom's products are used by patients and healthcare professionals worldwide to improve diabetes management and reduce complications associated with the condition.
Company News
DexCom faces a class action securities lawsuit alleging the company made unauthorized design changes to its G6 and G7 glucose monitoring devices without FDA approval, rendering them less reliable and presenting health risks to users. The complaint claims defendants overstated the devices' enhancements and concealed the true scope of issues, expos...
The article discusses two promising healthcare stocks for long-term investors: Pharmaceuticals and DexCom. Both companies offer strong growth potential in their respective markets of cystic fibrosis treatments and continuous glucose monitoring devices.
U.S. markets stabilized on Tuesday with subdued trading, awaiting a House vote on ending the government shutdown. Tech stocks experienced modest declines, while commodities like oil and silver showed gains.
The article highlights three stocks with potential dividend and growth opportunities in 2025: Schlumberger (SLB), General Electric Aerospace (GE), and DexCom (DXCM), each offering unique investment prospects in energy, aerospace, and medical technology sectors.
DexCom, Inc. is scheduled to release its second-quarter 2024 results on July 25. The company's revenues are expected to grow 19% year-over-year, driven by increased product volume and global awareness of its continuous glucose monitoring system. However, rising costs and competition may have weighed on its performance.
